对于性结肠炎患者对整合素抑制剂的治疗反应的组织学预测因素
Takuya Kimizuka1, Atsushi Yoshida1, Fumiaki Ueno1
1Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Japan.
Inflammatory intestinal diseases
|October 9, 2025
概括
性结肠炎 (UC) 活检中的大型淋巴卵泡可以预测对整合素抑制剂的反应. 这一组织学发现可以帮助个性化UC患者的先进治疗选择.
科学领域:
- 胃肠病学 胃肠病学
- 组织病理学 组织病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 预测性结肠炎 (UC) 中先进疗法的治疗疗效至关重要.
- 很少有研究确定了UC治疗反应的预测性组织学因素.
- 治疗前活检样本的传统组织学可以预测对整合素抑制剂的反应.
研究的目的:
- 确定是否传统的治疗前组织学内镜活检样本可以预测UC患者对整合素抑制剂的反应.
- 为了确定与对整合素抑制剂的初级反应 (PR) 相关的组织学因素.
主要方法:
- 单中心回顾性研究,分析整合素抑制剂启动前的组织病理学发现.
- 主要响应 (PR) 被定义为14周内部分梅奥得分下降≥3个点.
- 后勤回归用于确定PR的预测因素.
主要成果:
- 分析了21名生物和Janus酶抑制剂先验UC患者.
- 大型淋巴卵泡 (LF) 在61.9%的患者中存在.
- 在57.1%的患者中实现了PR;91.7%的响应者患有LF.
- 脊髓炎的存在与反应显著相关 (76.9%对12.5%,p=0.01).
结论:
- 活检样本中大型淋巴卵泡 (LF) 的存在预测了UC中对整合素抑制剂的反应.
- 传统的组织学检查可以帮助预测UC的先进疗法对治疗反应.
更多相关视频
06:31Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
1.5K
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
8.0K
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
637
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
637
Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456
Inflammatory Bowel Disease I: Ulcerative Colitis
894
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
894
